Feature | May 16, 2013

St. Jude Medical Gains European Approval of PCI 3-D Vessel Reconstruction Technology

System provides real-time 360-degree panoramic view of the arteries in 3-D, integrated FFR

The Ilumien Optis can reconstruct 3-D images on vessels and stent placements using OCT technology.

May 16, 2013 — St. Jude Medical gained CE mark approval of its Ilumien Optis percutaneous coronary intervention (PCI) optimization system to better visualize stent planning and navigation. The system will be on display for the first time in Europe during EuroPCR.

The Ilumien Optis system provides enhancements to the Ilumien system, including first-of-its-kind stent planning software tools to aid in the treatment of coronary artery disease (CAD). The Ilumien platform integrates both fractional flow reserve (FFR) technology to measure pressure inside the coronary arteries and intravascular optical coherence tomography (OCT) imaging technology, in one system.

Featuring a faster, high-powered laser, the Ilumien Optis system offers twice the resolution for microscopic examination of disease inside the artery to assist with stent placement. The real-time, 3-D reconstruction offers a 360-degree panoramic view of the vessel, making it easier for physicians to visualize the area they are treating. St. Jude Medical is the only company to provide these tools together in an integrated platform.

“OCT technology has become increasingly important to help diagnose and treat patients with coronary artery disease. The Ilumien Optis system is a significant advancement in intravascular imaging technology allowing physicians to comprehensively assess more vessel in less time and more easily plan their PCI procedure. The three-dimensional format of the Ilumien Optis system provides a more true-to-life perspective of the arteries, which allows for individual decision making and precise guidance of stent placement to optimize coronary interventions, said Dr. Giulio Guagliumi, cardiovascular department of Ospedale Papa Giovanni XXIII, Bergamo, Italy.

The OCT technology in the new Ilumien Optis system uses the Dragonfly Duo Imaging Catheter to capture near-infrared light imaging and measure important vessel characteristics otherwise invisible or difficult to assess with older imaging technology. When used with the system, the Dragonfly Duo catheter offers faster, longer pull-backs, which allow the physician to assess more of the patient’s artery in less time.

The wireless PressureWire Aeris technology that is integrated into the platform measures pressure differences in blood flow within the coronary arteries leading to the heart, and determines the severity of any narrowings or blockages. The FFR pressure guidewire is directed along the vessel, taking measurements as the guidewire is pulled back through the artery. Knowing which specific blockages are causing the patient’s blood flow to be ineffective helps guide the interventional cardiologist in determining which lesions warrant stenting, resulting in improved patient outcomes and reduced health care costs.

The FFR and OCT measurements captured by the Ilumien Optis system allow physicians to more easily differentiate plaque build-up and determine if the narrowed arteries are causing ischemia, ultimately assisting in stent placement. The automated stent planning tools provide immediate information for assessment and real-time analysis, which is intended to streamline workflow, potentially helping physicians diagnose their patients more quickly.

For more information: sjm.com

 

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Cardioband, valtech, Edwards Lifesciences, transcatheter mitral repair, transcatheter tricuspid valve repair, transcatheter annuloplasty

An illustration of how the transcatheter Cardioband System can used as a non-surgical form on annuloplasty repair. 

News | Heart Valve Technology| December 02, 2016
December 2, 2016 — Edwards Lifesciences Corp.
Sponsored Content | Videos | Robotic Systems| November 22, 2016
Corindus Vascular Robotics received U.S.
Overlay Init